AUS
NZ
UK
CA
USA
IND
Healthcare
BARD1 Life Sciences Granted R&D Tax Incentive Refund From ATO
May 27, 2019 04:20 PM AEST| By Team Kalkine MediaBARD1 Life Sciences Limited (ASX: BD1) operates in the medical line of business. The company, based in Australia, is a medical technology company which aims to develop and commercialise non-invasive diagnostic tests towards detecting an early stage c...
Resonance Health’s Current Suite Of Products And Expanding R&D Initiatives
May 27, 2019 03:54 PM AEST| By Team Kalkine MediaAustralia-based Resonance Health (ASX: RHT) is a healthcare sector company which specialises in developing and offering non-invasive medical imaging software and analysis services to clinicians for the diagnosis and management of human diseases; and...
Noxopharm Expands LuPIN Trial On Promising Interim Results That Relate To Veyonda®
May 27, 2019 02:21 PM AEST| By Team Kalkine MediaClinical-Stage drug development company, Noxopharm Limited (ASX: NOX) has announced a notable expansion of its investigator-initiated trial, LuPIN, at the back of encouraging interim results observed to date in LuPIN trial Veyonda? (NOX66) dose-findi...
Federal Court Approved Healthscope’s Takeover by Brookfield’s ANZ Hospitals; CEO Quits
May 27, 2019 02:13 PM AEST| By Team Kalkine MediaHealthscope Limited (ASX: HSO) is a ?healthcare company operating and managing a vast network of clinics, hospitals, and physicians, that provide emergency care, cancer care, pediatric services, pathology tests as well as complex surgeries. There is...
Healthcare Stocks At High Levels-PME & CUV
May 26, 2019 09:30 AM AEST| By Team Kalkine MediaAccording to a ?Health expenditure Australia? report for 2016 ? 2017 by Australian Institute of Health and Welfare (AIHW), Australia spent nearly $181 billion on health which accounts to an astonishing 10% of the entire economy. The real growth, afte...
Starpharma’s DEP® Irinotecan Outperforms Other leading Cancer Drugs
May 24, 2019 11:45 PM AEST| By Team Kalkine MediaStarpharma Holdings Limited (ASX: SPL) is based out of Melbourne. The company has two primary development programs, which are VivaGel? portfolio and DEP? drug delivery. Besides this, it is developing various products internally and others through und...
Antisense Therapeutics: Phase II Clinical Trial Of ATL1102 Is Fully Enrolled Now
May 24, 2019 05:16 PM AEST| By Team Kalkine MediaOn Friday, Antisense Therapeutics Limited (ASX: ANP) announced that Phase II clinical trial of its immunomodulatory therapy, ATL1102 for Duchenne Muscular Dystrophy (DMD) is now fully enrolled. The trial is an open-label six-month dosage trial and is...
2 Healthcare Stocks - LBT, RNO
May 23, 2019 11:44 PM AEST| By Team Kalkine MediaLBT Innovations Limited LBT Innovations Limited (ASX: LBT), established in 2004 and based in Adelaide, Australia, is engaged in the research and development of technologies for the healthcare and laboratory supply markets in Australia, Switzerland,...
A Glimpse at Neuren’s neuroscience drug therapy pipeline
May 23, 2019 03:26 PM AEST| By Team Kalkine MediaA biopharmaceutical company headquartered in Australia, Neuren Pharmaceuticals Limited (ASX: NEU) is engaged in the development of new therapies for ?neurodevelopmental disorders with a high unmet need, characterised by impaired connections and signa...
AFP’s FY19 Performance - What investors need to know?
May 23, 2019 01:50 PM AEST| By Team Kalkine MediaAFT Pharmaceuticals Limited (ASX: AFP) is a growing pharma company with its head office based out of New Zealand. It officially was listed on ASX in December 2015. On 22nd May 2019, the company published its Investor Presentation and Annual Report, c...
Rhythm Biosciences’ QMS Granted ISO Certification
May 23, 2019 01:40 PM AEST| By Team Kalkine MediaRhythm Biosciences Limited (ASX: RHY) is an ASX listed healthcare company which is developing a diagnostic tool for the early detection of colorectal cancer, which causes high mortality rate. It has its lead product, ColoSTAT?, a simple and low-cost...
Oventus Medical’s O2 Vent® Eases Into Largest Dental Group In North Carolina, USA
May 22, 2019 10:59 PM AEST| By Team Kalkine MediaOventus Medical Limited (ASX: OVN) is a healthcare sector company, engaged in the development of oral devices that are used for the therapeutic treatment of breathing disorders, particularly sleep apnea. On 22nd May 2019, Oventus Medical Limited ann...
Sienna Cancer Diagnostics Granted SIEN-NETTM Chinese Patent
May 22, 2019 10:21 PM AEST| By Team Kalkine MediaThe medical technology company, Sienna Cancer Diagnostics Limited (ASX: SDX) is based in Australia. It develops and commercialises innovative cancer related tests. Besides Australia, SDX operates in Asia, The United States, Europe, Latin America. The...
A lens Over Telix Annual General Meeting
May 22, 2019 10:03 PM AEST| By Team Kalkine MediaTelix Pharmaceuticals Limited (ASX: TLX) is a clinical-stage biopharmaceutical company focused on the development of products for the treatment of prostate,?renal (kidney) and glioblastoma (brain) cancer. On 22 May 2019, TLX released a transcript of...
Exopharm Provides A Market Update On Its Proprietary Exosome Product
May 22, 2019 07:56 PM AEST| By Team Kalkine MediaAustralian Biopharmaceutical company Exopharm Limited (ASX: EX1) is focused on developing regenerative medicine with the use of exosomes as therapeutic agents. It seeks to commercialise its proprietary product, Exomeres?, earlier known as Plexaris?....
Botanix Pharmaceuticals appointed Mr Vince Ippolito as President
May 22, 2019 04:42 PM AEST| By Team Kalkine MediaBotanix Pharmaceuticals Ltd?(ASX: BOT) is a dermatology company. It is based in Perth, Australia and Philadelphia, PA. The company aims to develop safe and effective topical treatments for skin conditions like acne, psoriasis and atopic dermatitis. I...
Noxopharm Flags High Rates Of Response From LuPIN Trial Veyonda® Dose-Finding Study
May 22, 2019 12:59 PM AEST| By Team Kalkine MediaAs per the latest announcements by Noxopharm Limited (ASX: NOX), the clinical-stage drug development company has now received positive interim results from its LuPIN trial Veyonda? (NOX66) dose-finding study focused on investigating 177Lu-PSMA-617 in...
Kazia Therapeutics collaborates with Alliance to investigate new drug, GDC-0084
May 21, 2019 01:42 PM AEST| By Team Kalkine MediaKazia Therapeutics Limited (ASX: KZA) caters to the health care sector and is based out of Sydney, Australia. It is a bio-tech company which focusses on innovative oncology. The company aims to bring out diversified portfolio of new cancer therapies....
Imugene Appoints Leading Biotechnology Executive and Entrepreneur-Dr Jens Eckstein
May 21, 2019 01:22 PM AEST| By Team Kalkine MediaImugene Limited (ASX: IMU) is a clinical stage immuno-oncology firm. The company is developing a range of new and novel immunotherapies that basically activates the immune system of the patients with cancer and eradicates tumours developed. The comp...
MedAdvisor’s 50:50 JV ZPM Signs MedExpress Drugstores as its First Customer
May 21, 2019 01:01 PM AEST| By Team Kalkine MediaAustralia?s leading digital medication management company, MedAdvisor Limited (ASX: MDR) on 20th May 2019, announced that its 50:50 joint venture company, Zuellig Pharma (ZP MedAdvisor Pte Ltd, ?ZPM?) has signed MedExpress Drugstores as its first cus...
Advertise your brand on Kalkine Media